Barriers associated with implementing asparaginase-based regimens in AYA patients with ALL
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Barriers associated with implementing asparaginase-based regimens in AYA patients with ALL
-
ナレーター：
-
著者：
The ALL Hub spoke with Luke Maese, University of Utah Huntsman Cancer Institute and Primary Children’s Hospital, Salt Lake City, US. We asked, What are the main barriers associated with implementing asparaginase-based regimens in adolescent and young adult (AYA) patients with ALL.
In this interview, Maese discussed the main challenges faced when treating AYA patients with ALL and the difficulties associated with facilitating the implementation of asparaginase-based regimens to treat this patient population.
This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Hosted on Acast. See acast.com/privacy for more information.